Journal of Clinical Oncology

Vol. 44, Issue 16_suppl Issue 16_suppl 2026
7213
Articles

Articles in this Issue

CURE AI as a predictor of TIGIT as a therapeutic target in pediatric cancers.

Vitalay Fomin, Amit Weiss, Tal Shor et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e22000

e22000 Background: Clinical trials are not able to study individual treatment effects as methods to do so have not...

Integrated clinical and genomic analysis of mediastinal germ cell tumors (GCT) with somatic transformation (SM): A multi-institutional cohort study.

Zachariah Thomas, Towfik Sebai, Andrew Johns et al. Jun 01, 2026 pp. 5029-5029 10.1200/jco.2026.44.16_suppl.5029

5029 Background: SM of GCT is a rare but lethal entity largely described in the context of testicular primaries. The disti...

Incorporating tumor pathological subtype into a multiparameter model: Improved accuracy in predicting prostate cancer extraprostatic extension.

Qingyuan Liang, Simeng Wen Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e17117

e17117 Background: Extraprostatic extension (EPE) at radical prostatectomy (RP) is associated with worse biochemical recur...

Immune checkpoint blockade (ICB) in advanced/metastatic leiomyosarcoma (LMS): Real-world cohort from MD Anderson.

Nassar El Assaad, Michael S. Nakazawa, Carlos Torrado et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e23545

e23545 Background: LMS is an aggressive soft-tissue sarcoma with an immunologically “cold” tumor microenvironment and hist...

Septicemia in acute lymphoblastic leukemia: Disparities in incidence, resource utilization, and mortality between pediatric and adult populations.

Rigved Virendra Jeurkar, Aishwarya Ramesh, Kamleshun Ramphul et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e18510

e18510 Background: Acute lymphoblastic leukemia (ALL) in adults has substantially worse outcomes than pediatric ALL, with...

Demographic patterns and survival outcomes in acute myeloid leukemia with t(6;9)(p23;q34); DEK–NUP214.

Filip J. Sadurski, Alifya Lokhandwala, Rohit Sharma Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e18553

e18553 Background: Acute myeloid leukemia (AML) with t(6;9)(p23;q34); DEK–NUP214 is a rare, adverse-risk cytogenetic subty...

Development and early implementation of a statewide comprehensive childhood cancer network to support pediatric oncology care and research.

Chris Hagemeyer, Nicole De Lara Puente, Jennifer McCafferty Fernandez Jun 01, 2026 pp. 10056-10056 10.1200/jco.2026.44.16_suppl.10056

10056 Background: Although pediatric cancer survival has improved substantially, families continue to face fragmented acce...

Competing risks of relapse and major organ failure after allogeneic hematopoietic cell transplantation.

Aakriti Adhikari, Himil Mahadevia, Vasu Bansal et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e18579

e18579 Background: Outcomes after allogeneic hematopoietic cell transplantation (allo-HCT) are often summarized using over...

Prognostic validation of artificial intelligence (AI)–based Stratipath breast risk stratification in TAILORx.

Johan Hartman, Robert James Gray, Mattias Rantalainen et al. Jun 01, 2026 pp. 555-555 10.1200/jco.2026.44.16_suppl.555

555 Background: Stratipath Breast is an AI-based prognostic medical device for risk stratification of early-stage breast c...

Hearing/vestibular dysfunction and longitudinal changes in psychosocial well-being among breast cancer survivors.

Jincong Q. Freeman, Armaan Jamal, Yijia Sun et al. Jun 01, 2026 pp. 12084-12084 10.1200/jco.2026.44.16_suppl.12084

12084 Background: Breast cancer treatment, in some cases, can cause hearing/vestibular dysfunction and negatively affect p...

Efficacy and safety of giredestrant (GIRE) in patients (pts) with estrogen receptor–positive, HER2-negative early breast cancer (ER+, HER2– eBC) in the phase III lidERA BC clinical trial: Results by menopausal status.

Peter Schmid, Charles E. Geyer, Miguel Martín et al. Jun 01, 2026 pp. 502-502 10.1200/jco.2026.44.16_suppl.502

502 Background: The lidERA BC trial (NCT04961996) demonstrated a statistically significant, clinically meaningful improvem...

Characteristics of patients with resectable early-stage non–small cell lung cancer treated with neoadjuvant chemoimmunotherapy or surgery ± adjuvant therapy.

Pragya Rai, Yu-Han Kao, Ashwini Arunachalam et al. Jun 01, 2026 pp. 8061-8061 10.1200/jco.2026.44.16_suppl.8061

8061 Background: The integration of immune checkpoint inhibitors (ICIs) into neoadjuvant, perioperative, and adjuvant trea...

Long-term cognitive impairment after CAR-T therapy compared with autologous stem cell transplantation.

Andrea Yun-En Sun, Po-Huang Chen, Cho-Hao Howard Lee Jun 01, 2026 pp. 7032-7032 10.1200/jco.2026.44.16_suppl.7032

7032 Background: Chimeric antigen receptor T-cell (CAR-T) therapy has transformed the management of relapsed and refractor...

Establishing a rapid diagnostic clinic at a tertiary care cancer center: The Indiana University Simon Comprehensive Cancer Center (IUSCCC) experience.

Emily Monroe, Emilie Jean-Marie, Towfik Sebai et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e13602

e13602 Background: Rapid diagnostic clinics (RDCs) are designed to accelerate evaluation and treatment for patients with s...

Analysis of an oral anticancer repository program and the impact on access to care.

Allyson Waller, Pooja Kumar, Sarah Hoffman et al. Jun 01, 2026 pp. 1506-1506 10.1200/jco.2026.44.16_suppl.1506

1506 Background: Patients with cancer face many barriers to timely access of oral anticancer agents, including financial t...

Preliminary clinical validation of a novel integrated genomic and epigenomic liquid biopsy assay (SPIRAL) in breast cancer.

Jue Wang, Yan Mao, Xiaoming Zha et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e22511

e22511 Background: Early detection of breast cancer is critical for improving patient outcomes. Liquid biopsy using circul...

Cachexia index, allostatic load, and body composition phenotypes in racially and ethnically diverse patients with metastatic colorectal cancer.

Brett Wagner, Yaroslava Bogdan, Victoria Gomez et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e15601

e15601 Background: Cachexia Index (CXI), which integrates muscle mass, nutritional status, and systemic inflammation, and...

FGFR-targeted therapies in advanced esophagogastric cancer: A systematic review and meta-analysis.

Muzammil Khan, Zobia Farooq, Juhi Ardeshna-Chovatiya et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e16053

e16053 Background: Esophagogastric cancer carries high mortality, with most patients diagnosed at advanced stages. In HER2...

A phase II exploratory study of iparomlimab and tuvonralimab (QL1706) combined with bevacizumab in patients with locally advanced or metastatic MSI-H/dMMR colorectal cancer.

Jun Wang, Yuekai Zhang, Yaping Guan et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.tps3677

TPS3677 Background: Microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) colorectal cancer (CRC) is high...

Towards hyper-sensitive MRD: Assessment of Enspyre as a cost-effective ctDNA detection technique using very large variant panels.

Maria Litovchenko, Iyelola Turner, Ana-Luisa Silva et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e15048

e15048 Background: Tumor-informed minimal residual disease (MRD) assays track patient-specific variants at significantly h...

Incidence of new keratinocyte cancers during pembrolizumab in resectable cutaneous squamous cell carcinoma: The De-Squamate study.

Rahul Ladwa, Brett Gordon Maxwell Hughes, Jenny HJ Lee et al. Jun 01, 2026 pp. 9582-9582 10.1200/jco.2026.44.16_suppl.9582

9582 Background: Patients with advanced cutaneous squamous cell carcinoma (cSCC) or basal cell carcinoma (BCC) frequently...

A real-world comparison of treatment and survival outcomes with zanubrutinib (zanu) and acalabrutinib (acala) monotherapy among patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL) in the United States.

Yucai Wang, Manasi Suryavanshi, Gregory Maglinte et al. Jun 01, 2026 pp. 7062-7062 10.1200/jco.2026.44.16_suppl.7062

7062 Background: MCL is a rare and aggressive subtype of B-cell non-Hodgkin lymphoma that remains incurable. Bruton tyrosi...

Outcomes and responsiveness of standard tyrosine kinase inhibitor dose versus dose de-escalation in chronic myeloid leukemia: A single-center retrospective study.

Mark Pusung, Christopher Eide, Andy Kaempf et al. Jun 01, 2026 pp. 6598-6598 10.1200/jco.2026.44.16_suppl.6598

6598 Background: Treatment with tyrosine kinase inhibitors (TKIs) enables patients with chronic myeloid leukemia (CML) to...

Comparative analysis of the tumor microenvironment in primary versus metastatic lymph node malignancies using The Cancer Genome Atlas data.

Thomas Noonan, Karen Dong-Tran, Vera Vaz et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e15189

e15189 Background: The tumor microenvironment (TME) plays a critical role in cancer progression, immune evasion, and metas...

Trends in soft tissue sarcoma of the heart in the United States (1975–2022): A SEER-based analysis.

Syed Hassan Ali, Sooraj Kumar, Madho Mal et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e23571

e23571 Background: Soft tissue sarcoma of the heart is an extremely rare malignancy with limited population-level data. Ev...

All Issues

Journal Info

Publisher Lippincott Williams & Wilkins
ISSN 0732-183X
E-ISSN 1527-7755
Subject Health Sciences
Language English
View Full Journal Page